- Home
- RDIB vs ACHV Comparison
RDIB vs ACHV Comparison
Compare RDIB & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDIB
- ACHV
- Stock Information
- Founded
- RDIB 1937
- ACHV N/A
- Country
- RDIB United States
- ACHV Canada
- Employees
- RDIB N/A
- ACHV N/A
- Industry
- RDIB Movies/Entertainment
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- RDIB Consumer Discretionary
- ACHV Health Care
- Exchange
- RDIB Nasdaq
- ACHV Nasdaq
- Market Cap
- RDIB 162.8M
- ACHV 149.6M
- IPO Year
- RDIB N/A
- ACHV N/A
- Fundamental
- Price
- RDIB $6.49
- ACHV $4.33
- Analyst Decision
- RDIB
- ACHV Strong Buy
- Analyst Count
- RDIB 0
- ACHV 5
- Target Price
- RDIB N/A
- ACHV $14.80
- AVG Volume (30 Days)
- RDIB 5.5K
- ACHV 116.0K
- Earning Date
- RDIB 12-03-2024
- ACHV 11-07-2024
- Dividend Yield
- RDIB N/A
- ACHV N/A
- EPS Growth
- RDIB N/A
- ACHV N/A
- EPS
- RDIB N/A
- ACHV N/A
- Revenue
- RDIB $197,270,000.00
- ACHV N/A
- Revenue This Year
- RDIB N/A
- ACHV N/A
- Revenue Next Year
- RDIB $13.64
- ACHV N/A
- P/E Ratio
- RDIB N/A
- ACHV N/A
- Revenue Growth
- RDIB N/A
- ACHV N/A
- 52 Week Low
- RDIB $5.96
- ACHV $3.03
- 52 Week High
- RDIB $21.34
- ACHV $5.98
- Technical
- Relative Strength Index (RSI)
- RDIB 42.22
- ACHV 40.62
- Support Level
- RDIB $5.96
- ACHV $4.12
- Resistance Level
- RDIB $6.78
- ACHV $4.46
- Average True Range (ATR)
- RDIB 0.44
- ACHV 0.24
- MACD
- RDIB -0.01
- ACHV -0.05
- Stochastic Oscillator
- RDIB 24.44
- ACHV 17.65
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial, and live theater assets.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.